PBH Prestige Consumer Healthcare Inc

---

---

---

---

---

---

---

---

Nature of Business

Prestige Consumer Healthcare Inc. (referred to herein as the “Company” or “we,” which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Consumer Healthcare Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (“OTC”) healthcare products to mass merchandisers, drug, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets.  Prestige Consumer Healthcare Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 7 to these Condensed Consolidated Financial Statements.

Economic Environment

There has been economic uncertainty in the United States and globally due to several factors, including global supply chain constraints, rising interest rates, a high inflationary environment and geopolitical events. We expect economic conditions will continue to be highly volatile and uncertain, put pressure on prices and supply, and could affect demand for our products. We have continued to see changes in the purchasing patterns of our consumers, including a reduction in the frequency of visits to retailers and a shift in many markets to purchasing our products online.

The volatile environment has impacted the supply of labor and raw materials and exacerbated rising input costs. Although we have not experienced a material disruption to our overall supply chain to date, we have and may continue to experience shortages, delays and backorders for certain ingredients and products, difficulty scheduling shipping for our products, as well as price increases from many of our suppliers for both shipping and product costs. In addition, labor shortages have impacted our manufacturing operations and may impact our ability to supply certain products to our customers. To date, these global conditions have not had a material negative impact on our operations, supply chain, overall costs or demand for most of our products or resulting aggregate sales and earnings, and, as such, it has also not materially negatively impacted our liquidity position. We continue to generate operating cash flows to meet our short-term liquidity needs. These circumstances could change, however, in this dynamic environment. If conditions cause further disruption in the global supply chain, the availability of labor and materials or otherwise further increase costs, it may materially affect our operations and those of third parties on which we rely, including causing material disruptions in the supply and distribution of our products. The extent to which these conditions impact our results and liquidity will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning global supply chain constraints, the high inflationary environment, global instability and the potential for further outbreaks of severe illnesses. These effects could have a material adverse impact on our business, liquidity, capital resources, and results of operations and those of the third parties on which we rely.

Basis of Presentation
The unaudited Condensed Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  All significant intercompany transactions and balances have been eliminated in consolidation.  In the opinion of management, these Condensed Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented.  Our fiscal year ends on March 31st of each year. References in these Condensed Consolidated Financial Statements or related notes to a year (e.g., 2024) mean our fiscal year ending or ended on March 31st of that year. Operating results for the six months ended September 30, 2023 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2024.  These unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023.

---

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.  Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. Our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and accounting for income taxes and related uncertain tax positions.  

Recently Adopted Accounting Pronouncements

In October 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires entities to apply Topic 606 to recognize and measure contract assets and liabilities in a business combination. This ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We adopted this standard effective April 1, 2023. The impact of the adoption of this new standard will depend on the magnitude of future acquisitions.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting and also issued subsequent amendments to the initial guidance (collectively, "Topic 848"). In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which extends the period of time preparers can utilize the reference rate reform relief guidance in Topic 848. Topic 848 provides optional guidance for contract modifications and certain hedging relationships associated with the transition from reference rates that are expected to be discontinued. On April 4, 2023, we entered into Amendment No. 8 ("ABL Amendment No. 8") to the Company's asset-based revolving credit facility originally entered into on January 31, 2012 (the "2012 ABL Revolver"). ABL Amendment No. 8 provides for the replacement of LIBOR with Secured Overnight Financing Rate ("SOFR") as our reference rate. On June 12, 2023, we entered into Amendment No. 7 ("Term Loan Amendment No. 7") to the Company’s term loan originally entered into on January 31, 2012 (the “2012 Term Loan”), effective July 1, 2023. Term Loan Amendment No. 7 provides for the replacement of LIBOR with SOFR as our reference rate. Effective July 1, 2023, we have transitioned all discontinued reference rates to SOFR. The adoption of the standard did not have a material impact on our Consolidated Financial Statements.

There were no other accounting pronouncements issued but not yet adopted by us that are expected to have a material impact on our Consolidated Financial Statements.

---

A reconciliation of the activity affecting intangible assets, net is as follows:

(In thousands)			Indefinite- Lived Trademarks						Finite-Lived Trademarks and Customer Relationships						Totals
Gross Carrying Amounts
Balance — March 31, 2023			$	2,168,902					$	411,118					$	2,580,020
Effects of foreign currency exchange rates			(3,082)						(785)						(3,867)
Balance — September 30, 2023			$	2,165,820					$	410,333					$	2,576,153
Accumulated Amortization
Balance — March 31, 2023			$	—					$	238,127					$	238,127
Additions			—						9,900						9,900
Effects of foreign currency exchange rates			—						(124)						(124)
Balance — September 30, 2023			$	—					$	247,903					$	247,903
Intangible assets, net - September 30, 2023			$	2,165,820					$	162,430					$	2,328,250

Amortization expense was $4.9 million and $9.9 million for the three and six months ended September 30, 2023, respectively, and $5.6 million and $11.3 million for the three and six months ended September 30, 2022, respectively.  

Finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 25 years, and the estimated amortization expense for each of the five succeeding years and the periods thereafter is as follows (in thousands):

---

(In thousands)
Year Ending March 31,			Amount
2024 (remaining six months ended March 31, 2024)			$	9,866
2025			18,061
2026			16,110
2027			14,519
2028			12,183
Thereafter			91,691
			$	162,430

The date of our annual impairment review was February 28, 2023, and we recorded impairment charges to intangible assets of $321.4 million in our March 31, 2023 financial statements. The assumptions subject to significant uncertainties in the impairment analysis include the discount rate utilized in the analysis, as well as future sales, gross margins, and advertising and marketing expenses. The discount rate assumption may be influenced by such factors as changes in interest rates and rates of inflation, which can have an impact on the determination of fair value. Additionally, should the related fair values of intangible assets be adversely affected as a result of declining sales or margins caused by competition, changing consumer needs or preferences, technological advances, changes in advertising and marketing expenses, or the potential impacts of supply chain constraints, labor shortages, or inflation, we may be required to record impairment charges in the future. As of September 30, 2023, no events have occurred that would indicate potential impairment of intangible assets.

We lease real estate and equipment for use in our operations.

The components of lease expense for the three and six months ended September 30, 2023 and 2022 were as follows:

						Three Months Ended September 30,												Six Months Ended September 30,
(In thousands)						2023						2022						2023						2022
Finance lease cost:
Amortization of right-of-use assets						$	664					$	664					$	1,329					$	1,329
Interest on lease liabilities						24						45						54						95
Operating lease cost						1,624						1,617						3,248						3,251
Short term lease cost						34						51						67						85
Variable lease cost						16,941						17,016						33,397						29,015
Total net lease cost						$	19,287					$	19,393					$	38,095					$	33,775

As of September 30, 2023, the maturities of lease liabilities were as follows:

(In thousands)
Year Ending March 31,						Operating Leases						Finance Lease						Total
2024 (remaining six months ending March 31, 2024)						$	3,564					$	1,461					$	5,025
2025						4,810						1,509						6,319
2026						2,328						96						2,424
2027						1,913						80						1,993
2028						1,433						—						1,433
Thereafter						254						—						254
Total undiscounted lease payments						14,302						3,146						17,448
Less amount of lease payments representing interest						(926)						(52)						(978)
Total present value of lease payments						$	13,376					$	3,094					$	16,470

---

Other accrued liabilities consist of the following:

(In thousands)			September 30, 2023						March 31, 2023
Accrued marketing costs			$	26,512					$	30,471
Accrued compensation costs			8,232						14,292
Accrued broker commissions			2,210						1,767
Income taxes payable			8,160						10,645
Accrued professional fees			4,323						4,254
Accrued production costs			6,003						5,700
Other accrued liabilities			4,640						5,395
			$	60,080					$	72,524

Long-term debt consists of the following, as of the dates indicated:

(In thousands, except percentages)						September 30, 2023						March 31, 2023
2021 Senior Notes bearing interest at 3.750%, with interest payable on April 1 and October 1 of each year. The 2021 Senior Notes mature on April 1, 2031.						$	600,000					$	600,000
2019 Senior Notes bearing interest at 5.125%, with interest payable on January 15 and July 15 of each year. The 2019 Senior Notes mature on January 15, 2028.						400,000						400,000
2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.50%, or an alternate base rate plus a margin of 1.00% per annum (at March 31, 2023) and SOFR plus a margin of 2.00% plus a credit spread adjustment (at September 30, 2023), due on July 1, 2028.						275,000						360,000
Long-term debt						1,275,000						1,360,000
Less: unamortized debt costs						(12,028)						(14,212)
Long-term debt, net						$	1,262,972					$	1,345,788

At September 30, 2023, we had no balance outstanding on the 2012 ABL Revolver and a borrowing capacity of $171.2 million.

On April 4, 2023, we entered into Amendment No. 8 to the 2012 ABL Revolver. ABL Amendment No. 8 provides for the replacement of LIBOR with SOFR as our reference rate.

On June 12, 2023, we entered into Term Loan Amendment No. 7 to the Company’s 2012 Term Loan, effective July 1, 2023. Term Loan Amendment No. 7 provides for the replacement of LIBOR with SOFR as our reference rate.

As of September 30, 2023, aggregate future principal payments required in accordance with the terms of the 2012 Term B-5 Loans under the 2012 Term Loan, the 2012 ABL Revolver and the indentures governing the senior unsecured notes due 2031 (the "2021 Senior Notes") and the senior unsecured notes due 2028 (the "2019 Senior Notes") are as follows:

---

For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts.

FASB Accounting Standards Codification ("ASC") 820, Fair Value Measurements, requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. ASC 820 established market (observable inputs) as the preferred source of fair value, to be followed by our assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created:

Level 1 - Quoted market prices for identical instruments in active markets;

Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and

Level 3 - Unobservable inputs developed by us using estimates and assumptions reflective of those that would be utilized by a market participant.

The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2021 Senior Notes, the 2019 Senior Notes, the 2012 Term B-5 Loans, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. The summary below details the carrying amounts and estimated fair values of these instruments at September 30, 2023 and March 31, 2023.

						September 30, 2023												March 31, 2023
(In thousands)						Carrying Value						Fair Value						Carrying Value						Fair Value
2019 Senior Notes						400,000						373,000						400,000						383,500
2021 Senior Notes						600,000						482,250						600,000						510,750
2012 Term B-5 Loans						275,000						275,000						360,000						359,550

We are authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share.  The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof.

Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders.  The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of outstanding stock having priority rights as to dividends.  No dividends have been declared or paid on our common stock through September 30, 2023.

---

On May 2, 2023, the Company's Board of Directors authorized the repurchase of up to $25.0 million of the Company's issued and outstanding common stock through May 31, 2024, utilizing open market transactions, transactions structured through investment banking institutions, in privately-negotiated transactions, by direct purchases of common stock or a combination of the foregoing in compliance with the applicable rules and regulations of the Securities and Exchange Commission. We completed the repurchase in the first quarter of fiscal 2024.

During the three and six months ended September 30, 2023 and 2022, we repurchased shares of our common stock and recorded them as treasury stock. Our share repurchases consisted of the following:

			Three Months Ended September 30,												Six Months Ended September 30,
			2023						2022						2023						2022
Shares repurchased pursuant to the provisions of the various employee restricted stock awards:
Number of shares			—						—						88,953						99,219
Average price per share			$	—					$	—					$61.92						$54.94
Total amount repurchased			$	—					$	—					$5.5 million						$5.5 million
Shares repurchased in conjunction with our share repurchase program:
Number of shares			—						236,681						426,479						914,236
Average price per share			$	—					$	51.85					$58.62						$54.69
Total amount repurchased			$	—					$12.3 million						$25.0 million						$50.0 million

Accumulated other comprehensive loss consisted of the following at September 30, 2023 and March 31, 2023:

(In thousands)			September 30, 2023						March 31, 2023
Components of Accumulated Other Comprehensive Loss
Cumulative translation adjustment			$	(36,710)					$	(32,280)
Unrecognized net gain on pension plans, net of tax of $(214) and $(214), respectively			716						716
Accumulated other comprehensive loss, net of tax			$	(35,994)					$	(31,564)

---

In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “2005 Plan”), which provided for grants of up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units ("RSUs") and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, our stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance under the 2005 Plan, among other changes.

On June 23, 2020, the Board of Directors adopted the Prestige Consumer Healthcare Inc. 2020 Long-Term Incentive Plan (the “2020 Plan”). The 2020 Plan became effective on August 4, 2020, upon the approval of the 2020 Plan by our stockholders. On June 23, 2020, a total of 2,827,210 shares were available for issuance under the 2020 Plan (comprised of 2,000,000 new shares plus 827,210 shares that were unissued under the 2005 Plan). Since the 2020 Plan became effective, all equity awards have been made from the 2020 Plan, and the Company will not grant any additional awards under the 2005 Plan.

---

The following table provides information regarding our stock-based compensation:

						Three Months Ended September 30,												Six Months Ended September 30,
(In thousands)						2023						2022						2023						2022
Pre-tax stock-based compensation costs charged against income						$	3,688					$	3,466					$	7,834					$	7,323
Income tax benefit recognized on compensation costs						$	263					$	338					$	669					$	875
Total fair value of options and RSUs vested during the period						$	987					$	64					$	12,213					$	10,289
Cash received from the exercise of stock options						$	2,155					$	—					$	9,183					$	1,489
Tax benefits realized from tax deductions resulting from RSU issuances and stock option exercises						$	263					$	—					$	1,139					$	2,895

At September 30, 2023, there were $3.8 million of unrecognized compensation costs related to unvested stock options under the 2005 Plan and the 2020 Plan, excluding an estimate for forfeitures which may occur.  We expect to recognize such costs over a weighted average period of 2.1 years. At September 30, 2023, there were $14.8 million of unrecognized compensation costs related to unvested RSUs and performance stock units ("PSUs") under the 2005 Plan and the 2020 Plan, excluding an estimate for forfeitures which may occur.  We expect to recognize such costs over a weighted average period of 1.9 years.

At September 30, 2023, there were 1.9 million shares available for issuance under the 2020 Plan.

Restricted Stock Units

The fair value of the RSUs is determined using the closing price of our common stock on the date of the grant. A summary of the RSUs granted under the 2005 Plan and the 2020 Plan is presented below:

RSUs						Shares (in thousands)						Weighted Average Grant-Date Fair Value
Six Months Ended September 30, 2022
Unvested at March 31, 2022						440.9						$	38.45
Granted						148.9						55.04
Incremental performance shares						42.4						—
Vested						(222.4)						32.05
Unvested at September 30, 2022						409.8						47.14
Vested at September 30, 2022						108.5						36.54
Six Months Ended September 30, 2023
Unvested at March 31, 2023						409.0						$	47.17
Granted						157.1						62.06
Incremental performance shares						41.4						—
Vested						(205.0)						43.17
Forfeited						(8.6)						53.72
Unvested at September 30, 2023						393.9						54.40
Vested at September 30, 2023						110.2						38.77

---

Options

The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions presented below:

						Six Months Ended September 30,
						2023						2022
Expected volatility						30.2% - 31.6%						30.8% - 30.9%
Expected dividends						$	—					$	—
Expected term in years						6.0 to 7.0						6.0 to 7.0
Risk-free rate						3.6% to 4.1%						2.8% to 2.9%
Weighted average grant date fair value of options granted						$	23.79					$	20.10

A summary of option activity under the 2005 Plan and the 2020 Plan is as follows:

Options						Shares (in thousands)						Weighted Average Exercise Price						Weighted Average Remaining Contractual Term (years)						Aggregate Intrinsic Value (in thousands)
Six Months Ended September 30, 2022
Outstanding at March 31, 2022						1,100.9						$	40.62
Granted						197.6						54.48
Exercised						(39.1)						38.04
Outstanding at September 30, 2022						1,259.4						42.88						6.6						$	10,963
Vested at September 30, 2022						830.8						40.04						5.4						$	9,403
Six Months Ended September 30, 2023
Outstanding at March 31, 2023						1,081.0						$	43.96
Granted						131.1						61.81
Exercised						(230.4)						39.85
Forfeited						(35.8)						54.81
Expired						(2.8)						54.47
Outstanding at September 30, 2023						943.1						47.00						6.3						$	10,166
Vested at September 30, 2023						644.7						43.19						5.2						$	9,025

The aggregate intrinsic value of options exercised during the six months ended September 30, 2023 was $4.7 million.

---

Our revenues are concentrated in the area of OTC Healthcare. We sell our products to mass merchandisers, drug, food, dollar, convenience and club stores and e-commerce channels. During the three and six months ended September 30, 2023, approximately 38.9% and 40.0%, respectively, of our gross revenues were derived from our five top selling brands. During the three and six months ended September 30, 2022, approximately 39.7% and 40.6%, respectively, of our gross revenues were derived from our five top selling brands. Walmart accounted for approximately 19.1% and 20.0%, respectively, of our gross revenues for the three and six months ended September 30, 2023. Walmart accounted for approximately 19.7% and 19.8%, respectively, of our gross revenues for the three and six months ended September 30, 2022. Amazon accounted for 10.3% of our gross revenues for the six months ended September 30, 2023. An additional customer, Walgreens, accounted for approximately 10.4% of our gross revenues for the three months ended September 30, 2022.

Our product distribution in the United States is managed by a third party through one primary distribution center in Clayton, Indiana. In addition, we operate one manufacturing facility for certain of our products located in Lynchburg, Virginia, which manufactures many of the Summer's Eve and Fleet products. A natural disaster, such as tornado, earthquake, flood, or fire, could damage our inventory and/or materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. In addition, a serious disruption caused by performance or contractual issues with our third-party distribution manager or labor shortages or public health emergencies at our distribution center or manufacturing facility could materially impact our product distribution. Any disruption could result in increased costs, expense and/or shipping times, and could cause us to incur customer fees and penalties. We could also incur significantly higher costs and experience longer lead times if we need to replace our distribution center, the third-party distribution manager or the manufacturing facility.  As a result, any serious disruption could have a material adverse effect on our business, financial condition and results of operations.

At September 30, 2023, we had relationships with 128 third-party manufacturers.  Of those, we had long-term contracts with 28 manufacturers that produced items that accounted for approximately 74.6% of gross sales for the six months ended September 30, 2023. At September 30, 2022, we had relationships with 130 third-party manufacturers.  Of those, we had long-term contracts with 27 manufacturers that produced items that accounted for approximately 71.3% of gross sales for the six months ended September 30, 2022. The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results of operations. Although we are continually in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach a timely agreement, which could have a material adverse effect on our business and results of operations.

Our current reportable segments consist of (i) North American OTC Healthcare and (ii) International OTC Healthcare. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and marketing expenses.

The tables below summarize information about our reportable segments.

---

			Three Months Ended September 30, 2023
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Total segment revenues*			$	244,423					$	41,893											$	286,316
Cost of sales			107,466						18,830												126,296
Gross profit			136,957						23,063												160,020
Advertising and marketing			35,389						4,713												40,102
Contribution margin			$	101,568					$	18,350											$	119,918
Other operating expenses																					31,668
Operating income																					$	88,250
* Intersegment revenues of $0.6 million were eliminated from the North American OTC Healthcare segment.

			Six Months Ended September 30, 2023
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Total segment revenues*			$	490,566					$	75,059											$	565,625
Cost of sales			217,542						33,390												250,932
Gross profit			273,024						41,669												314,693
Advertising and marketing			66,790						9,543												76,333
Contribution margin			$	206,234					$	32,126											$	238,360
Other operating expenses																					64,916
Operating income																					$	173,444
* Intersegment revenues of $2.0 million were eliminated from the North American OTC Healthcare segment.

			Three Months Ended September 30, 2022
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Total segment revenues*			$	252,054					$	37,219											$	289,273
Cost of sales			113,533						14,731												128,264
Gross profit			138,521						22,488												161,009
Advertising and marketing			39,316						4,503												43,819
Contribution margin			$	99,205					$	17,985											$	117,190
Other operating expenses																					32,806
Operating income																					$	84,384
* Intersegment revenues of $1.1 million were eliminated from the North American OTC Healthcare segment.

---

			Six Months Ended September 30, 2022
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Total segment revenues*			$	494,572					$	71,760											$	566,332
Cost of sales			216,454						28,750												245,204
Gross profit			278,118						43,010												321,128
Advertising and marketing			74,728						9,042												83,770
Contribution margin			$	203,390					$	33,968											$	237,358
Other operating expenses																					65,960
Operating income																					$	171,398
* Intersegment revenues of $1.7 million were eliminated from the North American OTC Healthcare segment.

The tables below summarize information about our segment revenues from similar product groups.

			Three Months Ended September 30, 2023
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Analgesics			$	29,976					$	1,386											$	31,362
Cough & Cold			25,970						7,263												33,233
Women's Health			55,000						7,072												62,072
Gastrointestinal			38,703						14,061												52,764
Eye & Ear Care			39,745						7,125												46,870
Dermatologicals			33,018						1,469												34,487
Oral Care			19,312						3,469												22,781
Other OTC			2,699						48												2,747
Total segment revenues			$	244,423					$	41,893											$	286,316

			Six Months Ended September 30, 2023
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Analgesics			$	57,158					$	2,228											$	59,386
Cough & Cold			46,344						13,315												59,659
Women's Health			109,955						12,028												121,983
Gastrointestinal			83,384						26,971												110,355
Eye & Ear Care			79,216						11,146												90,362
Dermatologicals			67,696						2,807												70,503
Oral Care			41,038						6,491												47,529
Other OTC			5,775						73												5,848
Total segment revenues			$	490,566					$	75,059											$	565,625

---

			Three Months Ended September 30, 2022
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Analgesics			$	32,750					$	541											$	33,291
Cough & Cold			24,058						7,168												31,226
Women's Health			59,379						4,745												64,124
Gastrointestinal			41,272						16,037												57,309
Eye & Ear Care			37,961						4,734												42,695
Dermatologicals			32,872						902												33,774
Oral Care			21,251						3,080												24,331
Other OTC			2,511						12												2,523
Total segment revenues			$	252,054					$	37,219											$	289,273

			Six Months Ended September 30, 2022
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Analgesics			$	60,547					$	994											$	61,541
Cough & Cold			45,650						13,439												59,089
Women's Health			120,563						9,612												130,175
Gastrointestinal			81,339						30,064												111,403
Eye & Ear Care			76,572						9,470												86,042
Dermatologicals			62,327						1,908												64,235
Oral Care			42,226						6,250												48,476
Other OTC			5,348						23												5,371
Total segment revenues			$	494,572					$	71,760											$	566,332

---

---

---

---

---

---

---

---

---

---

---

---

---

The following is a summary of the material terms of the contracts, instructions or written plans for the purchase or sale of the Company's securities adopted or terminated by our officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) or directors during the three months ended September 30, 2023:

Name and Position

Date

Action

Satisfies Affirmative Defense under Rule 10b5-(c)

Expiration Date

Total Ordinary Shares to be Sold

Mary Beth Fritz

September 15, 2023

Adoption

X

September 27, 2024

15,871

Senior Vice President

Quality & Regulatory Affairs

---

---

v3.23.3

Cover Page - shares	6 Months Ended
	Sep. 30, 2023	Oct. 27, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-32433
Entity Registrant Name	PRESTIGE CONSUMER HEALTHCARE INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-1297589
Entity Address, Address Line One	660 White Plains Road
Entity Address, City or Town	Tarrytown
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10591
City Area Code	914
Local Phone Number	524-6800
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	PBH
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		49,618,585
Entity Central Index Key	0001295947
Current Fiscal Year End Date	--03-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Amendment Flag	false

v3.23.3

Condensed Consolidated Statements of Income and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues
Total revenues	$ 286,316	$ 289,273	$ 565,625	$ 566,332
Cost of Sales
Cost of sales excluding depreciation	124,324	126,384	246,978	241,380
Cost of sales depreciation	1,972	1,880	3,954	3,824
Cost of sales	126,296	128,264	250,932	245,204
Gross profit	160,020	161,009	314,693	321,128
Operating Expenses
Advertising and marketing	40,102	43,819	76,333	83,770
General and administrative	25,997	26,438	53,684	53,152
Depreciation and amortization	5,671	6,368	11,232	12,808
Total operating expenses	71,770	76,625	141,249	149,730
Operating income	88,250	84,384	173,444	171,398
Other expense
Interest expense, net	17,606	16,979	35,325	32,271
Other (income) expense, net	229	812	(1,009)	1,637
Total other expense, net	17,835	17,791	34,316	33,908
Income before income taxes	70,415	66,593	139,128	137,490
Provision for income taxes	16,856	15,570	32,293	31,195
Net income	$ 53,559	$ 51,023	$ 106,835	$ 106,295
Earnings per share:
Basic (in USD per share)	$ 1.08	$ 1.02	$ 2.15	$ 2.12
Diluted (in USD per share)	$ 1.07	$ 1.02	$ 2.13	$ 2.11
Weighted average shares outstanding:
Basic (in shares)	49,687	49,804	49,727	50,033
Diluted (in shares)	50,081	50,265	50,138	50,496
Comprehensive income, net of tax:
Currency translation adjustments	$ (3,784)	$ (7,118)	$ (4,430)	$ (16,637)
Net loss on termination of pension plan	0	0	0	(790)
Total other comprehensive loss	(3,784)	(7,118)	(4,430)	(17,427)
Comprehensive income	49,775	43,905	102,405	88,868
Net sales
Revenues
Total revenues	286,307	289,264	565,606	566,288
Other revenues
Revenues
Total revenues	$ 9	$ 9	$ 19	$ 44

v3.23.3

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Mar. 31, 2023
Current assets
Cash and cash equivalents	$ 60,067	$ 58,489
Accounts receivable, net of allowance of $21,994 and $20,205, respectively	158,456	167,016
Inventories	161,283	162,121
Prepaid expenses and other current assets	8,392	4,117
Total current assets	388,198	391,743
Property, plant and equipment, net	70,700	70,412
Operating lease right-of-use assets	12,134	14,923
Finance lease right-of-use assets, net	2,870	4,200
Goodwill	526,860	527,553
Intangible assets, net	2,328,250	2,341,893
Other long-term assets	3,862	3,005
Total Assets	3,332,874	3,353,729
Current liabilities
Accounts payable	44,381	62,743
Accrued interest payable	15,635	15,688
Operating lease liabilities, current portion	6,732	6,926
Finance lease liabilities, current portion	2,876	2,834
Other accrued liabilities	60,080	72,524
Total current liabilities	129,704	160,715
Long-term debt, net	1,262,972	1,345,788
Deferred income tax liabilities	388,481	380,434
Long-term operating lease liabilities, net of current portion	6,644	9,876
Long-term finance lease liabilities, net of current portion	218	1,667
Other long-term liabilities	8,896	8,165
Total Liabilities	1,796,915	1,906,645
Commitments and Contingencies — Note 14
Stockholders' Equity
Preferred stock - $0.01 par value; Authorized - 5,000 shares; Issued and outstanding - None	0	0
Common stock - $0.01 par value; Authorized - 250,000 shares; Issued - 55,291 shares at September 30, 2023 and 54,857 shares at March 31, 2023	552	548
Additional paid-in capital	552,369	535,356
Treasury stock, at cost - 5,680 shares at September 30, 2023 and 5,165 shares at March 31, 2023	(219,661)	(189,114)
Accumulated other comprehensive loss, net of tax	(35,994)	(31,564)
Retained earnings	1,238,693	1,131,858
Total Stockholders' Equity	1,535,959	1,447,084
Total Liabilities and Stockholders' Equity	$ 3,332,874	$ 3,353,729

v3.23.3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2023	Mar. 31, 2023
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable, current	$ 21,994	$ 20,205
Stockholders' Equity:
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	55,291,000	54,857,000
Treasury stock (in shares)	5,680,000	5,165,000

v3.23.3

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive (Loss)	Retained Earnings
Common stock, beginning balance (in shares) at Mar. 31, 2022		54,430,000
Equity, beginning balance at Mar. 31, 2022	$ 1,577,611	$ 544	$ 515,583	$ (133,648)	$ (19,032)	$ 1,214,164
Treasury stock, beginning balance (in shares) at Mar. 31, 2022				4,151,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 7,323		7,323
Exercise of stock options (in shares)	39,100	39,000
Exercise of stock options	$ 1,489	$ 1	1,488
Issuance of shares related to restricted stock (in shares)		221,000
Issuance of shares related to restricted stock	0	$ 2	(2)
Treasury share repurchases (in shares)				1,013,000
Treasury share repurchases	(55,450)			$ (55,450)
Net income	106,295					106,295
Comprehensive loss	(17,427)				(17,427)
Common stock, ending balance (in shares) at Sep. 30, 2022		54,690,000
Equity, ending balance at Sep. 30, 2022	1,619,841	$ 547	524,392	$ (189,098)	(36,459)	1,320,459
Treasury stock, ending balance (in shares) at Sep. 30, 2022				5,164,000
Common stock, beginning balance (in shares) at Jun. 30, 2022		54,690,000
Equity, beginning balance at Jun. 30, 2022	1,584,743	$ 547	520,926	$ (176,825)	(29,341)	1,269,436
Treasury stock, beginning balance (in shares) at Jun. 30, 2022				4,928,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	3,466		3,466
Treasury share repurchases (in shares)				236,000
Treasury share repurchases	(12,273)			$ (12,273)
Net income	51,023					51,023
Comprehensive loss	(7,118)				(7,118)
Common stock, ending balance (in shares) at Sep. 30, 2022		54,690,000
Equity, ending balance at Sep. 30, 2022	1,619,841	$ 547	524,392	$ (189,098)	(36,459)	1,320,459
Treasury stock, ending balance (in shares) at Sep. 30, 2022				5,164,000
Common stock, beginning balance (in shares) at Mar. 31, 2023		54,857,000
Equity, beginning balance at Mar. 31, 2023	$ 1,447,084	$ 548	535,356	$ (189,114)	(31,564)	1,131,858
Treasury stock, beginning balance (in shares) at Mar. 31, 2023	5,165,000			5,165,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 7,834		7,834
Exercise of stock options (in shares)	230,400	231,000
Exercise of stock options	$ 9,183	$ 2	9,181
Issuance of shares related to restricted stock (in shares)		203,000
Issuance of shares related to restricted stock	0	$ 2	(2)
Treasury share repurchases (in shares)				515,000
Treasury share repurchases	(30,547)			$ (30,547)
Net income	106,835					106,835
Comprehensive loss	(4,430)				(4,430)
Common stock, ending balance (in shares) at Sep. 30, 2023		55,291,000
Equity, ending balance at Sep. 30, 2023	$ 1,535,959	$ 552	552,369	$ (219,661)	(35,994)	1,238,693
Treasury stock, ending balance (in shares) at Sep. 30, 2023	5,680,000			5,680,000
Common stock, beginning balance (in shares) at Jun. 30, 2023		55,220,000
Equity, beginning balance at Jun. 30, 2023	$ 1,480,295	$ 552	546,526	$ (219,707)	(32,210)	1,185,134
Treasury stock, beginning balance (in shares) at Jun. 30, 2023				5,680,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	3,688		3,688
Exercise of stock options (in shares)		58,000
Exercise of stock options	2,155	$ 0	2,155
Issuance of shares related to restricted stock (in shares)		13,000
Treasury share repurchases	46			$ 46
Net income	53,559					53,559
Comprehensive loss	(3,784)				(3,784)
Common stock, ending balance (in shares) at Sep. 30, 2023		55,291,000
Equity, ending balance at Sep. 30, 2023	$ 1,535,959	$ 552	$ 552,369	$ (219,661)	$ (35,994)	$ 1,238,693
Treasury stock, ending balance (in shares) at Sep. 30, 2023	5,680,000			5,680,000

v3.23.3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating Activities
Net income	$ 106,835	$ 106,295
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	15,186	16,632
Loss on disposal of property and equipment	191	94
Deferred income taxes	9,721	4,211
Amortization of debt origination costs	2,302	1,798
Stock-based compensation costs	7,834	7,323
Non-cash operating lease cost	2,816	2,984
Other	0	447
Changes in operating assets and liabilities:
Accounts receivable	4,415	(8,276)
Inventories	223	(21,810)
Prepaid expenses and other current assets	(3,814)	(1,501)
Accounts payable	(18,820)	1,016
Accrued liabilities	(11,764)	9,788
Operating lease liabilities	(3,493)	(3,201)
Other	(1,085)	(13)
Net cash provided by operating activities	110,547	115,787
Investing Activities
Purchases of property, plant and equipment	(4,411)	(3,423)
Other	3,800	0
Net cash provided by (used in) investing activities	(611)	(3,423)
Financing Activities
Term loan repayments	(85,000)	(40,000)
Borrowings under revolving credit agreement	0	20,000
Repayments under revolving credit agreement	0	(20,000)
Payments of finance leases	(1,403)	(1,369)
Proceeds from exercise of stock options	9,183	1,489
Fair value of shares surrendered as payment of tax withholding	(5,508)	(5,450)
Repurchase of common stock	(25,000)	(50,000)
Net cash used in financing activities	(107,728)	(95,330)
Effects of exchange rate changes on cash and cash equivalents	(630)	(1,777)
Increase (decrease) in cash and cash equivalents	1,578	15,257
Cash and cash equivalents - beginning of period	58,489	27,185
Cash and cash equivalents - end of period	60,067	42,442
Supplemental Cash Flow Information
Interest paid	33,706	19,016
Income taxes paid	$ 25,118	$ 15,689

v3.23.3

Business and Basis of Presentation	6 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Presentation	Business and Basis of Presentation Nature of Business Prestige Consumer Healthcare Inc. (referred to herein as the “Company” or “we,” which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Consumer Healthcare Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (“OTC”) healthcare products to mass merchandisers, drug, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets.  Prestige Consumer Healthcare Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 7 to these Condensed Consolidated Financial Statements. Economic Environment There has been economic uncertainty in the United States and globally due to several factors, including global supply chain constraints, rising interest rates, a high inflationary environment and geopolitical events. We expect economic conditions will continue to be highly volatile and uncertain, put pressure on prices and supply, and could affect demand for our products. We have continued to see changes in the purchasing patterns of our consumers, including a reduction in the frequency of visits to retailers and a shift in many markets to purchasing our products online. The volatile environment has impacted the supply of labor and raw materials and exacerbated rising input costs. Although we have not experienced a material disruption to our overall supply chain to date, we have and may continue to experience shortages, delays and backorders for certain ingredients and products, difficulty scheduling shipping for our products, as well as price increases from many of our suppliers for both shipping and product costs. In addition, labor shortages have impacted our manufacturing operations and may impact our ability to supply certain products to our customers. To date, these global conditions have not had a material negative impact on our operations, supply chain, overall costs or demand for most of our products or resulting aggregate sales and earnings, and, as such, it has also not materially negatively impacted our liquidity position. We continue to generate operating cash flows to meet our short-term liquidity needs. These circumstances could change, however, in this dynamic environment. If conditions cause further disruption in the global supply chain, the availability of labor and materials or otherwise further increase costs, it may materially affect our operations and those of third parties on which we rely, including causing material disruptions in the supply and distribution of our products. The extent to which these conditions impact our results and liquidity will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning global supply chain constraints, the high inflationary environment, global instability and the potential for further outbreaks of severe illnesses. These effects could have a material adverse impact on our business, liquidity, capital resources, and results of operations and those of the third parties on which we rely. Basis of Presentation The unaudited Condensed Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  All significant intercompany transactions and balances have been eliminated in consolidation.  In the opinion of management, these Condensed Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented.  Our fiscal year ends on March 31st of each year. References in these Condensed Consolidated Financial Statements or related notes to a year (e.g., 2024) mean our fiscal year ending or ended on March 31st of that year. Operating results for the six months ended September 30, 2023 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2024.  These unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.  Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. Our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and accounting for income taxes and related uncertain tax positions.   Recently Adopted Accounting Pronouncements In October 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires entities to apply Topic 606 to recognize and measure contract assets and liabilities in a business combination. This ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We adopted this standard effective April 1, 2023. The impact of the adoption of this new standard will depend on the magnitude of future acquisitions. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting and also issued subsequent amendments to the initial guidance (collectively, "Topic 848"). In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which extends the period of time preparers can utilize the reference rate reform relief guidance in Topic 848. Topic 848 provides optional guidance for contract modifications and certain hedging relationships associated with the transition from reference rates that are expected to be discontinued. On April 4, 2023, we entered into Amendment No. 8 ("ABL Amendment No. 8") to the Company's asset-based revolving credit facility originally entered into on January 31, 2012 (the "2012 ABL Revolver"). ABL Amendment No. 8 provides for the replacement of LIBOR with Secured Overnight Financing Rate ("SOFR") as our reference rate. On June 12, 2023, we entered into Amendment No. 7 ("Term Loan Amendment No. 7") to the Company’s term loan originally entered into on January 31, 2012 (the “2012 Term Loan”), effective July 1, 2023. Term Loan Amendment No. 7 provides for the replacement of LIBOR with SOFR as our reference rate. Effective July 1, 2023, we have transitioned all discontinued reference rates to SOFR. The adoption of the standard did not have a material impact on our Consolidated Financial Statements. There were no other accounting pronouncements issued but not yet adopted by us that are expected to have a material impact on our Consolidated Financial Statements.

v3.23.3

Inventories	6 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Inventories	InventoriesInventories consist of the following: (In thousands) September 30, 2023 March 31, 2023 Components of Inventories Packaging and raw materials $ 22,742  $ 20,634  Work in process 233  220  Finished goods 138,308  141,267  Inventories $ 161,283  $ 162,121  Inventories are carried and depicted above at the lower of cost or net realizable value, which includes a reduction in inventory values of $6.0 million at September 30, 2023 and $5.8 million at March 31, 2023 related to obsolete and slow-moving inventory.

v3.23.3

Goodwill	6 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC Healthcare International OTC Healthcare Consolidated Balance - March 31, 2023 Goodwill $ 711,452  $ 30,204  $ 741,656  Accumulated impairment loss (212,516) (1,587) (214,103) Balance - March 31, 2023 498,936  28,617  527,553  Effects of foreign currency exchange rates —  (693) (693) Balance - September 30, 2023 Goodwill 711,452  29,511  740,963  Accumulated impairment loss (212,516) (1,587) (214,103) Balance - September 30, 2023 $ 498,936  $ 27,924  $ 526,860  The date of our annual impairment review was February 28, 2023, and we recorded impairment charges to goodwill of $48.8 million in our March 31, 2023 financial statements. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties related to future sales, gross margins, and advertising and marketing expenses, which can be impacted by increases in competition, changing consumer preferences, technical advances, supply chain constraints, labor shortages, and inflation. The discount rate assumption may be influenced by such factors as changes in interest rates and rates of inflation, which can have an impact on the determination of fair value. If these assumptions are adversely affected, we may be required to record impairment charges in the future. As of September 30, 2023, we determined no events have occurred that would indicate potential impairment of goodwill.

v3.23.3

Intangible Assets, net	6 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Intangible Assets, net A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Lived Trademarks Finite-Lived Trademarks and Customer Relationships Totals Gross Carrying Amounts Balance — March 31, 2023 $ 2,168,902  $ 411,118  $ 2,580,020  Effects of foreign currency exchange rates (3,082) (785) (3,867) Balance — September 30, 2023 $ 2,165,820  $ 410,333  $ 2,576,153          Accumulated Amortization       Balance — March 31, 2023 $ —  $ 238,127  $ 238,127  Additions —  9,900  9,900  Effects of foreign currency exchange rates —  (124) (124) Balance — September 30, 2023 $ —  $ 247,903  $ 247,903  Intangible assets, net - September 30, 2023 $ 2,165,820  $ 162,430  $ 2,328,250  Amortization expense was $4.9 million and $9.9 million for the three and six months ended September 30, 2023, respectively, and $5.6 million and $11.3 million for the three and six months ended September 30, 2022, respectively.   Finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 25 years, and the estimated amortization expense for each of the five succeeding years and the periods thereafter is as follows (in thousands): (In thousands) Year Ending March 31, Amount 2024 (remaining six months ended March 31, 2024) $ 9,866  2025 18,061  2026 16,110  2027 14,519  2028 12,183  Thereafter 91,691  $ 162,430  The date of our annual impairment review was February 28, 2023, and we recorded impairment charges to intangible assets of $321.4 million in our March 31, 2023 financial statements. The assumptions subject to significant uncertainties in the impairment analysis include the discount rate utilized in the analysis, as well as future sales, gross margins, and advertising and marketing expenses. The discount rate assumption may be influenced by such factors as changes in interest rates and rates of inflation, which can have an impact on the determination of fair value. Additionally, should the related fair values of intangible assets be adversely affected as a result of declining sales or margins caused by competition, changing consumer needs or preferences, technological advances, changes in advertising and marketing expenses, or the potential impacts of supply chain constraints, labor shortages, or inflation, we may be required to record impairment charges in the future. As of September 30, 2023, no events have occurred that would indicate potential impairment of intangible assets.

v3.23.3

Leases	6 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Leases	Leases We lease real estate and equipment for use in our operations. The components of lease expense for the three and six months ended September 30, 2023 and 2022 were as follows: Three Months Ended September 30, Six Months Ended September 30, (In thousands) 2023 2022 2023 2022 Finance lease cost:      Amortization of right-of-use assets $ 664  $ 664  $ 1,329  $ 1,329       Interest on lease liabilities 24  45  54  95  Operating lease cost 1,624  1,617  3,248  3,251  Short term lease cost 34  51  67  85  Variable lease cost 16,941  17,016  33,397  29,015  Total net lease cost $ 19,287  $ 19,393  $ 38,095  $ 33,775  As of September 30, 2023, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Finance Lease Total 2024 (remaining six months ending March 31, 2024) $ 3,564  $ 1,461  $ 5,025  2025 4,810  1,509  6,319  2026 2,328  96  2,424  2027 1,913  80  1,993  2028 1,433  —  1,433  Thereafter 254  —  254  Total undiscounted lease payments 14,302  3,146  17,448  Less amount of lease payments representing interest (926) (52) (978) Total present value of lease payments $ 13,376  $ 3,094  $ 16,470  The weighted average remaining lease term and weighted average discount rate were as follows: September 30, 2023 Weighted average remaining lease term (years) Operating leases 3.02 Finance leases 1.23 Weighted average discount rate Operating leases 3.62  % Finance leases 2.94  %
Leases	Leases We lease real estate and equipment for use in our operations. The components of lease expense for the three and six months ended September 30, 2023 and 2022 were as follows: Three Months Ended September 30, Six Months Ended September 30, (In thousands) 2023 2022 2023 2022 Finance lease cost:      Amortization of right-of-use assets $ 664  $ 664  $ 1,329  $ 1,329       Interest on lease liabilities 24  45  54  95  Operating lease cost 1,624  1,617  3,248  3,251  Short term lease cost 34  51  67  85  Variable lease cost 16,941  17,016  33,397  29,015  Total net lease cost $ 19,287  $ 19,393  $ 38,095  $ 33,775  As of September 30, 2023, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Finance Lease Total 2024 (remaining six months ending March 31, 2024) $ 3,564  $ 1,461  $ 5,025  2025 4,810  1,509  6,319  2026 2,328  96  2,424  2027 1,913  80  1,993  2028 1,433  —  1,433  Thereafter 254  —  254  Total undiscounted lease payments 14,302  3,146  17,448  Less amount of lease payments representing interest (926) (52) (978) Total present value of lease payments $ 13,376  $ 3,094  $ 16,470  The weighted average remaining lease term and weighted average discount rate were as follows: September 30, 2023 Weighted average remaining lease term (years) Operating leases 3.02 Finance leases 1.23 Weighted average discount rate Operating leases 3.62  % Finance leases 2.94  %

v3.23.3

Other Accrued Liabilities	6 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other Accrued Liabilities Other accrued liabilities consist of the following: (In thousands) September 30, 2023 March 31, 2023 Accrued marketing costs $ 26,512  $ 30,471  Accrued compensation costs 8,232  14,292  Accrued broker commissions 2,210  1,767  Income taxes payable 8,160  10,645  Accrued professional fees 4,323  4,254  Accrued production costs 6,003  5,700  Other accrued liabilities 4,640  5,395  $ 60,080  $ 72,524

v3.23.3

Long-Term Debt	6 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) September 30, 2023 March 31, 2023 2021 Senior Notes bearing interest at 3.750%, with interest payable on April 1 and October 1 of each year. The 2021 Senior Notes mature on April 1, 2031. $ 600,000  $ 600,000  2019 Senior Notes bearing interest at 5.125%, with interest payable on January 15 and July 15 of each year. The 2019 Senior Notes mature on January 15, 2028. 400,000  400,000  2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.50%, or an alternate base rate plus a margin of 1.00% per annum (at March 31, 2023) and SOFR plus a margin of 2.00% plus a credit spread adjustment (at September 30, 2023), due on July 1, 2028. 275,000  360,000  Long-term debt 1,275,000  1,360,000  Less: unamortized debt costs (12,028) (14,212) Long-term debt, net $ 1,262,972  $ 1,345,788  At September 30, 2023, we had no balance outstanding on the 2012 ABL Revolver and a borrowing capacity of $171.2 million. On April 4, 2023, we entered into Amendment No. 8 to the 2012 ABL Revolver. ABL Amendment No. 8 provides for the replacement of LIBOR with SOFR as our reference rate. On June 12, 2023, we entered into Term Loan Amendment No. 7 to the Company’s 2012 Term Loan, effective July 1, 2023. Term Loan Amendment No. 7 provides for the replacement of LIBOR with SOFR as our reference rate. As of September 30, 2023, aggregate future principal payments required in accordance with the terms of the 2012 Term B-5 Loans under the 2012 Term Loan, the 2012 ABL Revolver and the indentures governing the senior unsecured notes due 2031 (the "2021 Senior Notes") and the senior unsecured notes due 2028 (the "2019 Senior Notes") are as follows: (In thousands) Year Ending March 31, Amount 2024 (remaining six months ending March 31, 2024) $ —  2025 —  2026 —  2027 —  2028 400,000  Thereafter 875,000  $ 1,275,000

v3.23.3

Fair Value Measurements	6 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts. FASB Accounting Standards Codification ("ASC") 820, Fair Value Measurements, requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. ASC 820 established market (observable inputs) as the preferred source of fair value, to be followed by our assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created: Level 1 - Quoted market prices for identical instruments in active markets; Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and Level 3 - Unobservable inputs developed by us using estimates and assumptions reflective of those that would be utilized by a market participant. The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2021 Senior Notes, the 2019 Senior Notes, the 2012 Term B-5 Loans, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. The summary below details the carrying amounts and estimated fair values of these instruments at September 30, 2023 and March 31, 2023. September 30, 2023 March 31, 2023 (In thousands) Carrying Value Fair Value Carrying Value Fair Value 2019 Senior Notes 400,000  373,000  400,000  383,500  2021 Senior Notes 600,000  482,250  600,000  510,750  2012 Term B-5 Loans 275,000  275,000  360,000  359,550  At September 30, 2023 and March 31, 2023, we did not have any assets or liabilities measured in Level 1 or 3.

v3.23.3

Stockholders' Equity	6 Months Ended
	Sep. 30, 2023
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity We are authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share.  The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders.  The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of outstanding stock having priority rights as to dividends.  No dividends have been declared or paid on our common stock through September 30, 2023. On May 2, 2023, the Company's Board of Directors authorized the repurchase of up to $25.0 million of the Company's issued and outstanding common stock through May 31, 2024, utilizing open market transactions, transactions structured through investment banking institutions, in privately-negotiated transactions, by direct purchases of common stock or a combination of the foregoing in compliance with the applicable rules and regulations of the Securities and Exchange Commission. We completed the repurchase in the first quarter of fiscal 2024. During the three and six months ended September 30, 2023 and 2022, we repurchased shares of our common stock and recorded them as treasury stock. Our share repurchases consisted of the following: Three Months Ended September 30, Six Months Ended September 30, 2023 2022 2023 2022 Shares repurchased pursuant to the provisions of the various employee restricted stock awards: Number of shares —  —  88,953  99,219  Average price per share $ —  $ —  $61.92 $54.94 Total amount repurchased $ —  $ —  $5.5 million $5.5 million Shares repurchased in conjunction with our share repurchase program: Number of shares —  236,681  426,479  914,236  Average price per share $ —  $ 51.85  $58.62 $54.69 Total amount repurchased $ —  $12.3 million $25.0 million $50.0 million

v3.23.3

Accumulated Other Comprehensive Loss	6 Months Ended
	Sep. 30, 2023
Stockholders' Equity Note [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss Accumulated other comprehensive loss consisted of the following at September 30, 2023 and March 31, 2023: (In thousands) September 30, 2023 March 31, 2023 Components of Accumulated Other Comprehensive Loss   Cumulative translation adjustment $ (36,710)   $ (32,280) Unrecognized net gain on pension plans, net of tax of $(214) and $(214), respectively 716  716  Accumulated other comprehensive loss, net of tax $ (35,994)   $ (31,564) As of September 30, 2023 and March 31, 2023, no amounts were reclassified from accumulated other comprehensive loss into earnings.

v3.23.3

Earnings Per Share	6 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per ShareThe following table sets forth the computation of basic and diluted earnings per share: Three Months Ended September 30, Six Months Ended September 30, (In thousands, except per share data) 2023 2022 2023 2022 Numerator Net income $ 53,559  $ 51,023  $ 106,835  $ 106,295        Denominator     Denominator for basic earnings per share — weighted average shares outstanding 49,687  49,804  49,727  50,033  Dilutive effect of unvested restricted stock units and options issued to employees and directors 394  461  411  463  Denominator for diluted earnings per share 50,081  50,265  50,138  50,496        Earnings per Common Share:     Basic earnings per share $ 1.08  $ 1.02  $ 2.15  $ 2.12        Diluted earnings per share $ 1.07  $ 1.02  $ 2.13  $ 2.11  For the three months ended September 30, 2023 and 2022, there were 0.3 million and 0.4 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive. For the six months ended September 30, 2023 and 2022, there were 0.3 million and 0.4 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.

v3.23.3

Stock-Based Compensation	6 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “2005 Plan”), which provided for grants of up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units ("RSUs") and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, our stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance under the 2005 Plan, among other changes. On June 23, 2020, the Board of Directors adopted the Prestige Consumer Healthcare Inc. 2020 Long-Term Incentive Plan (the “2020 Plan”). The 2020 Plan became effective on August 4, 2020, upon the approval of the 2020 Plan by our stockholders. On June 23, 2020, a total of 2,827,210 shares were available for issuance under the 2020 Plan (comprised of 2,000,000 new shares plus 827,210 shares that were unissued under the 2005 Plan). Since the 2020 Plan became effective, all equity awards have been made from the 2020 Plan, and the Company will not grant any additional awards under the 2005 Plan. The following table provides information regarding our stock-based compensation: Three Months Ended September 30, Six Months Ended September 30, (In thousands) 2023 2022 2023 2022 Pre-tax stock-based compensation costs charged against income $ 3,688  $ 3,466  $ 7,834  $ 7,323  Income tax benefit recognized on compensation costs $ 263  $ 338  $ 669  $ 875  Total fair value of options and RSUs vested during the period $ 987  $ 64  $ 12,213  $ 10,289  Cash received from the exercise of stock options $ 2,155  $ —  $ 9,183  $ 1,489  Tax benefits realized from tax deductions resulting from RSU issuances and stock option exercises $ 263  $ —  $ 1,139  $ 2,895  At September 30, 2023, there were $3.8 million of unrecognized compensation costs related to unvested stock options under the 2005 Plan and the 2020 Plan, excluding an estimate for forfeitures which may occur.  We expect to recognize such costs over a weighted average period of 2.1 years. At September 30, 2023, there were $14.8 million of unrecognized compensation costs related to unvested RSUs and performance stock units ("PSUs") under the 2005 Plan and the 2020 Plan, excluding an estimate for forfeitures which may occur.  We expect to recognize such costs over a weighted average period of 1.9 years. At September 30, 2023, there were 1.9 million shares available for issuance under the 2020 Plan. Restricted Stock Units The fair value of the RSUs is determined using the closing price of our common stock on the date of the grant. A summary of the RSUs granted under the 2005 Plan and the 2020 Plan is presented below:       RSUs   Shares (in thousands) Weighted Average Grant-Date Fair Value Six Months Ended September 30, 2022 Unvested at March 31, 2022 440.9  $ 38.45  Granted 148.9  55.04  Incremental performance shares 42.4  —  Vested (222.4) 32.05  Unvested at September 30, 2022 409.8  47.14  Vested at September 30, 2022 108.5  36.54        Six Months Ended September 30, 2023 Unvested at March 31, 2023 409.0  $ 47.17  Granted 157.1  62.06  Incremental performance shares 41.4  —  Vested (205.0) 43.17  Forfeited (8.6) 53.72  Unvested at September 30, 2023 393.9  54.40  Vested at September 30, 2023 110.2  38.77  Options The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions presented below:   Six Months Ended September 30,   2023   2022 Expected volatility 30.2% - 31.6%   30.8% - 30.9% Expected dividends $ —    $ —  Expected term in years 6.0 to 7.0   6.0 to 7.0 Risk-free rate 3.6% to 4.1%   2.8% to 2.9% Weighted average grant date fair value of options granted $ 23.79  $ 20.10  A summary of option activity under the 2005 Plan and the 2020 Plan is as follows:         Options     Shares (in thousands) Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Six Months Ended September 30, 2022 Outstanding at March 31, 2022 1,100.9  $ 40.62  Granted 197.6  54.48  Exercised (39.1) 38.04  Outstanding at September 30, 2022 1,259.4  42.88  6.6 $ 10,963  Vested at September 30, 2022 830.8  40.04  5.4 $ 9,403  Six Months Ended September 30, 2023         Outstanding at March 31, 2023 1,081.0  $ 43.96  Granted 131.1  61.81  Exercised (230.4) 39.85  Forfeited (35.8) 54.81  Expired (2.8) 54.47  Outstanding at September 30, 2023 943.1  47.00  6.3 $ 10,166  Vested at September 30, 2023 644.7  43.19  5.2 $ 9,025  The aggregate intrinsic value of options exercised during the six months ended September 30, 2023 was $4.7 million.

v3.23.3

Income Taxes	6 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesIncome taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur. The effective tax rates used in the calculation of income taxes were 23.9% and 23.4% for the three months ended September 30, 2023 and 2022, respectively. The effective tax rates used in the calculation of income taxes were 23.2% and 22.7% for the six months ended September 30, 2023 and 2022, respectively. The increase in the effective tax rate for the three and six months ended September 30, 2023, compared to the three and six months ended September 30, 2022, was due to discrete items primarily pertaining to state tax rate legislative changes and stock-based compensation.

v3.23.3

Commitments and Contingencies	6 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and ContingenciesWe are involved from time to time in legal matters and other claims incidental to our business.  We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss.  These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted.  The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve.  In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement).  We believe the reasonably possible losses from resolution of routine legal matters and other claims incidental to our business will not have a material effect on our financial statements.

v3.23.3

Concentrations of Risk	6 Months Ended
	Sep. 30, 2023
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk Our revenues are concentrated in the area of OTC Healthcare. We sell our products to mass merchandisers, drug, food, dollar, convenience and club stores and e-commerce channels. During the three and six months ended September 30, 2023, approximately 38.9% and 40.0%, respectively, of our gross revenues were derived from our five top selling brands. During the three and six months ended September 30, 2022, approximately 39.7% and 40.6%, respectively, of our gross revenues were derived from our five top selling brands. Walmart accounted for approximately 19.1% and 20.0%, respectively, of our gross revenues for the three and six months ended September 30, 2023. Walmart accounted for approximately 19.7% and 19.8%, respectively, of our gross revenues for the three and six months ended September 30, 2022. Amazon accounted for 10.3% of our gross revenues for the six months ended September 30, 2023. An additional customer, Walgreens, accounted for approximately 10.4% of our gross revenues for the three months ended September 30, 2022. Our product distribution in the United States is managed by a third party through one primary distribution center in Clayton, Indiana. In addition, we operate one manufacturing facility for certain of our products located in Lynchburg, Virginia, which manufactures many of the Summer's Eve and Fleet products. A natural disaster, such as tornado, earthquake, flood, or fire, could damage our inventory and/or materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. In addition, a serious disruption caused by performance or contractual issues with our third-party distribution manager or labor shortages or public health emergencies at our distribution center or manufacturing facility could materially impact our product distribution. Any disruption could result in increased costs, expense and/or shipping times, and could cause us to incur customer fees and penalties. We could also incur significantly higher costs and experience longer lead times if we need to replace our distribution center, the third-party distribution manager or the manufacturing facility.  As a result, any serious disruption could have a material adverse effect on our business, financial condition and results of operations. At September 30, 2023, we had relationships with 128 third-party manufacturers.  Of those, we had long-term contracts with 28 manufacturers that produced items that accounted for approximately 74.6% of gross sales for the six months ended September 30, 2023. At September 30, 2022, we had relationships with 130 third-party manufacturers.  Of those, we had long-term contracts with 27 manufacturers that produced items that accounted for approximately 71.3% of gross sales for the six months ended September 30, 2022. The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results of operations. Although we are continually in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach a timely agreement, which could have a material adverse effect on our business and results of operations.

v3.23.3

Business Segments	6 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Business Segments	Business Segments Our current reportable segments consist of (i) North American OTC Healthcare and (ii) International OTC Healthcare. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and marketing expenses. The tables below summarize information about our reportable segments.   Three Months Ended September 30, 2023 (In thousands) North American OTC Healthcare International OTC Healthcare Consolidated Total segment revenues* $ 244,423  $ 41,893  $ 286,316  Cost of sales 107,466  18,830  126,296  Gross profit 136,957  23,063  160,020  Advertising and marketing 35,389  4,713  40,102  Contribution margin $ 101,568  $ 18,350  $ 119,918  Other operating expenses   31,668  Operating income   $ 88,250  * Intersegment revenues of $0.6 million were eliminated from the North American OTC Healthcare segment.   Six Months Ended September 30, 2023 (In thousands) North American OTC Healthcare International OTC Healthcare Consolidated Total segment revenues* $ 490,566  $ 75,059  $ 565,625  Cost of sales 217,542  33,390  250,932  Gross profit 273,024  41,669  314,693  Advertising and marketing 66,790  9,543  76,333  Contribution margin $ 206,234  $ 32,126  $ 238,360  Other operating expenses   64,916  Operating income   $ 173,444  * Intersegment revenues of $2.0 million were eliminated from the North American OTC Healthcare segment.   Three Months Ended September 30, 2022 (In thousands) North American OTC Healthcare International OTC Healthcare Consolidated Total segment revenues* $ 252,054  $ 37,219  $ 289,273  Cost of sales 113,533  14,731  128,264  Gross profit 138,521  22,488  161,009  Advertising and marketing 39,316  4,503  43,819  Contribution margin $ 99,205  $ 17,985  $ 117,190  Other operating expenses   32,806  Operating income   $ 84,384  * Intersegment revenues of $1.1 million were eliminated from the North American OTC Healthcare segment.   Six Months Ended September 30, 2022 (In thousands) North American OTC Healthcare International OTC Healthcare Consolidated Total segment revenues* $ 494,572  $ 71,760  $ 566,332  Cost of sales 216,454  28,750  245,204  Gross profit 278,118  43,010  321,128  Advertising and marketing 74,728  9,042  83,770  Contribution margin $ 203,390  $ 33,968  $ 237,358  Other operating expenses   65,960  Operating income   $ 171,398  * Intersegment revenues of $1.7 million were eliminated from the North American OTC Healthcare segment. The tables below summarize information about our segment revenues from similar product groups. Three Months Ended September 30, 2023 (In thousands) North American OTC Healthcare International OTC Healthcare Consolidated Analgesics $ 29,976  $ 1,386  $ 31,362  Cough & Cold 25,970  7,263  33,233  Women's Health 55,000  7,072  62,072  Gastrointestinal 38,703  14,061  52,764  Eye & Ear Care 39,745  7,125  46,870  Dermatologicals 33,018  1,469  34,487  Oral Care 19,312  3,469  22,781  Other OTC 2,699  48  2,747  Total segment revenues $ 244,423  $ 41,893  $ 286,316  Six Months Ended September 30, 2023 (In thousands) North American OTC Healthcare International OTC Healthcare Consolidated Analgesics $ 57,158  $ 2,228  $ 59,386  Cough & Cold 46,344  13,315  59,659  Women's Health 109,955  12,028  121,983  Gastrointestinal 83,384  26,971  110,355  Eye & Ear Care 79,216  11,146  90,362  Dermatologicals 67,696  2,807  70,503  Oral Care 41,038  6,491  47,529  Other OTC 5,775  73  5,848  Total segment revenues $ 490,566  $ 75,059  $ 565,625  Three Months Ended September 30, 2022 (In thousands) North American OTC Healthcare International OTC Healthcare Consolidated Analgesics $ 32,750  $ 541  $ 33,291  Cough & Cold 24,058  7,168  31,226  Women's Health 59,379  4,745  64,124  Gastrointestinal 41,272  16,037  57,309  Eye & Ear Care 37,961  4,734  42,695  Dermatologicals 32,872  902  33,774  Oral Care 21,251  3,080  24,331  Other OTC 2,511  12  2,523  Total segment revenues $ 252,054  $ 37,219  $ 289,273  Six Months Ended September 30, 2022 (In thousands) North American OTC Healthcare International OTC Healthcare Consolidated Analgesics $ 60,547  $ 994  $ 61,541  Cough & Cold 45,650  13,439  59,089  Women's Health 120,563  9,612  130,175  Gastrointestinal 81,339  30,064  111,403  Eye & Ear Care 76,572  9,470  86,042  Dermatologicals 62,327  1,908  64,235  Oral Care 42,226  6,250  48,476  Other OTC 5,348  23  5,371  Total segment revenues $ 494,572  $ 71,760  $ 566,332

v3.23.3

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net income	$ 53,559	$ 51,023	$ 106,835	$ 106,295

v3.23.3

Insider Trading Arrangements	3 Months Ended	6 Months Ended
	Sep. 30, 2023 shares	Sep. 30, 2023 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		The following is a summary of the material terms of the contracts, instructions or written plans for the purchase or sale of the Company's securities adopted or terminated by our officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) or directors during the three months ended September 30, 2023: Name and Position Date Action Satisfies Affirmative Defense under Rule 10b5-(c) Expiration Date Total Ordinary Shares to be Sold Mary Beth Fritz September 15, 2023 Adoption X September 27, 2024 15,871  Senior Vice President Quality & Regulatory Affairs
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	true
Non-Rule 10b5-1 Arrangement Terminated	false
Mary Beth Fritz [Member]
Trading Arrangements, by Individual
Name	Mary Beth Fritz
Title	Senior Vice President
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	September 15, 2023
Arrangement Duration	378 days
Aggregate Available	15,871	15,871

v3.23.3

Business and Basis of Presentation (Policies)	6 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The unaudited Condensed Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  All significant intercompany transactions and balances have been eliminated in consolidation.  In the opinion of management, these Condensed Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented.  Our fiscal year ends on March 31st of each year. References in these Condensed Consolidated Financial Statements or related notes to a year (e.g., 2024) mean our fiscal year ending or ended on March 31st of that year. Operating results for the six months ended September 30, 2023 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2024.  These unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023.
Use of Estimates	Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.  Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. Our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and accounting for income taxes and related uncertain tax positions.
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements	Recently Adopted Accounting Pronouncements In October 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires entities to apply Topic 606 to recognize and measure contract assets and liabilities in a business combination. This ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We adopted this standard effective April 1, 2023. The impact of the adoption of this new standard will depend on the magnitude of future acquisitions. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting and also issued subsequent amendments to the initial guidance (collectively, "Topic 848"). In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which extends the period of time preparers can utilize the reference rate reform relief guidance in Topic 848. Topic 848 provides optional guidance for contract modifications and certain hedging relationships associated with the transition from reference rates that are expected to be discontinued. On April 4, 2023, we entered into Amendment No. 8 ("ABL Amendment No. 8") to the Company's asset-based revolving credit facility originally entered into on January 31, 2012 (the "2012 ABL Revolver"). ABL Amendment No. 8 provides for the replacement of LIBOR with Secured Overnight Financing Rate ("SOFR") as our reference rate. On June 12, 2023, we entered into Amendment No. 7 ("Term Loan Amendment No. 7") to the Company’s term loan originally entered into on January 31, 2012 (the “2012 Term Loan”), effective July 1, 2023. Term Loan Amendment No. 7 provides for the replacement of LIBOR with SOFR as our reference rate. Effective July 1, 2023, we have transitioned all discontinued reference rates to SOFR. The adoption of the standard did not have a material impact on our Consolidated Financial Statements. There were no other accounting pronouncements issued but not yet adopted by us that are expected to have a material impact on our Consolidated Financial Statements.

v3.23.3

Inventories (Tables)	6 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Inventories	Inventories consist of the following: (In thousands) September 30, 2023 March 31, 2023 Components of Inventories Packaging and raw materials $ 22,742  $ 20,634  Work in process 233  220  Finished goods 138,308  141,267  Inventories $ 161,283  $ 162,121

v3.23.3

Goodwill (Tables)	6 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Reconciliation of the Activity Affecting Goodwill	A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC Healthcare International OTC Healthcare Consolidated Balance - March 31, 2023 Goodwill $ 711,452  $ 30,204  $ 741,656  Accumulated impairment loss (212,516) (1,587) (214,103) Balance - March 31, 2023 498,936  28,617  527,553  Effects of foreign currency exchange rates —  (693) (693) Balance - September 30, 2023 Goodwill 711,452  29,511  740,963  Accumulated impairment loss (212,516) (1,587) (214,103) Balance - September 30, 2023 $ 498,936  $ 27,924  $ 526,860

v3.23.3

Intangible Assets, net (Tables)	6 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Reconciliation of the Activity Affecting Finite Lived Intangible Assets	A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Lived Trademarks Finite-Lived Trademarks and Customer Relationships Totals Gross Carrying Amounts Balance — March 31, 2023 $ 2,168,902  $ 411,118  $ 2,580,020  Effects of foreign currency exchange rates (3,082) (785) (3,867) Balance — September 30, 2023 $ 2,165,820  $ 410,333  $ 2,576,153          Accumulated Amortization       Balance — March 31, 2023 $ —  $ 238,127  $ 238,127  Additions —  9,900  9,900  Effects of foreign currency exchange rates —  (124) (124) Balance — September 30, 2023 $ —  $ 247,903  $ 247,903  Intangible assets, net - September 30, 2023 $ 2,165,820  $ 162,430  $ 2,328,250
Reconciliation of the Activity Affecting Indefinite Lived Intangible Assets	A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Lived Trademarks Finite-Lived Trademarks and Customer Relationships Totals Gross Carrying Amounts Balance — March 31, 2023 $ 2,168,902  $ 411,118  $ 2,580,020  Effects of foreign currency exchange rates (3,082) (785) (3,867) Balance — September 30, 2023 $ 2,165,820  $ 410,333  $ 2,576,153          Accumulated Amortization       Balance — March 31, 2023 $ —  $ 238,127  $ 238,127  Additions —  9,900  9,900  Effects of foreign currency exchange rates —  (124) (124) Balance — September 30, 2023 $ —  $ 247,903  $ 247,903  Intangible assets, net - September 30, 2023 $ 2,165,820  $ 162,430  $ 2,328,250
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 25 years, and the estimated amortization expense for each of the five succeeding years and the periods thereafter is as follows (in thousands): (In thousands) Year Ending March 31, Amount 2024 (remaining six months ended March 31, 2024) $ 9,866  2025 18,061  2026 16,110  2027 14,519  2028 12,183  Thereafter 91,691  $ 162,430

v3.23.3

Leases (Tables)	6 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Components of Lease Expense	The components of lease expense for the three and six months ended September 30, 2023 and 2022 were as follows: Three Months Ended September 30, Six Months Ended September 30, (In thousands) 2023 2022 2023 2022 Finance lease cost:      Amortization of right-of-use assets $ 664  $ 664  $ 1,329  $ 1,329       Interest on lease liabilities 24  45  54  95  Operating lease cost 1,624  1,617  3,248  3,251  Short term lease cost 34  51  67  85  Variable lease cost 16,941  17,016  33,397  29,015  Total net lease cost $ 19,287  $ 19,393  $ 38,095  $ 33,775  The weighted average remaining lease term and weighted average discount rate were as follows: September 30, 2023 Weighted average remaining lease term (years) Operating leases 3.02 Finance leases 1.23 Weighted average discount rate Operating leases 3.62  % Finance leases 2.94  %
Maturities of Operating Leases	As of September 30, 2023, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Finance Lease Total 2024 (remaining six months ending March 31, 2024) $ 3,564  $ 1,461  $ 5,025  2025 4,810  1,509  6,319  2026 2,328  96  2,424  2027 1,913  80  1,993  2028 1,433  —  1,433  Thereafter 254  —  254  Total undiscounted lease payments 14,302  3,146  17,448  Less amount of lease payments representing interest (926) (52) (978) Total present value of lease payments $ 13,376  $ 3,094  $ 16,470
Maturities of Finance Leases	As of September 30, 2023, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Finance Lease Total 2024 (remaining six months ending March 31, 2024) $ 3,564  $ 1,461  $ 5,025  2025 4,810  1,509  6,319  2026 2,328  96  2,424  2027 1,913  80  1,993  2028 1,433  —  1,433  Thereafter 254  —  254  Total undiscounted lease payments 14,302  3,146  17,448  Less amount of lease payments representing interest (926) (52) (978) Total present value of lease payments $ 13,376  $ 3,094  $ 16,470

v3.23.3

Other Accrued Liabilities (Tables)	6 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other accrued liabilities consist of the following: (In thousands) September 30, 2023 March 31, 2023 Accrued marketing costs $ 26,512  $ 30,471  Accrued compensation costs 8,232  14,292  Accrued broker commissions 2,210  1,767  Income taxes payable 8,160  10,645  Accrued professional fees 4,323  4,254  Accrued production costs 6,003  5,700  Other accrued liabilities 4,640  5,395  $ 60,080  $ 72,524

v3.23.3

Long-Term Debt (Tables)	6 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) September 30, 2023 March 31, 2023 2021 Senior Notes bearing interest at 3.750%, with interest payable on April 1 and October 1 of each year. The 2021 Senior Notes mature on April 1, 2031. $ 600,000  $ 600,000  2019 Senior Notes bearing interest at 5.125%, with interest payable on January 15 and July 15 of each year. The 2019 Senior Notes mature on January 15, 2028. 400,000  400,000  2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.50%, or an alternate base rate plus a margin of 1.00% per annum (at March 31, 2023) and SOFR plus a margin of 2.00% plus a credit spread adjustment (at September 30, 2023), due on July 1, 2028. 275,000  360,000  Long-term debt 1,275,000  1,360,000  Less: unamortized debt costs (12,028) (14,212) Long-term debt, net $ 1,262,972  $ 1,345,788
Aggregate Future Principal Payments	As of September 30, 2023, aggregate future principal payments required in accordance with the terms of the 2012 Term B-5 Loans under the 2012 Term Loan, the 2012 ABL Revolver and the indentures governing the senior unsecured notes due 2031 (the "2021 Senior Notes") and the senior unsecured notes due 2028 (the "2019 Senior Notes") are as follows: (In thousands) Year Ending March 31, Amount 2024 (remaining six months ending March 31, 2024) $ —  2025 —  2026 —  2027 —  2028 400,000  Thereafter 875,000  $ 1,275,000

v3.23.3

Fair Value Measurements (Tables)	6 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Summary of Carry Amounts and Fair Value Measurements	The summary below details the carrying amounts and estimated fair values of these instruments at September 30, 2023 and March 31, 2023. September 30, 2023 March 31, 2023 (In thousands) Carrying Value Fair Value Carrying Value Fair Value 2019 Senior Notes 400,000  373,000  400,000  383,500  2021 Senior Notes 600,000  482,250  600,000  510,750  2012 Term B-5 Loans 275,000  275,000  360,000  359,550

v3.23.3

Stockholders' Equity (Tables)	6 Months Ended
	Sep. 30, 2023
Stockholders' Equity Note [Abstract]
Class of Treasury Stock	Our share repurchases consisted of the following: Three Months Ended September 30, Six Months Ended September 30, 2023 2022 2023 2022 Shares repurchased pursuant to the provisions of the various employee restricted stock awards: Number of shares —  —  88,953  99,219  Average price per share $ —  $ —  $61.92 $54.94 Total amount repurchased $ —  $ —  $5.5 million $5.5 million Shares repurchased in conjunction with our share repurchase program: Number of shares —  236,681  426,479  914,236  Average price per share $ —  $ 51.85  $58.62 $54.69 Total amount repurchased $ —  $12.3 million $25.0 million $50.0 million

v3.23.3

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Sep. 30, 2023
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Loss	Accumulated other comprehensive loss consisted of the following at September 30, 2023 and March 31, 2023: (In thousands) September 30, 2023 March 31, 2023 Components of Accumulated Other Comprehensive Loss   Cumulative translation adjustment $ (36,710)   $ (32,280) Unrecognized net gain on pension plans, net of tax of $(214) and $(214), respectively 716  716  Accumulated other comprehensive loss, net of tax $ (35,994)   $ (31,564)

v3.23.3

Earnings Per Share (Tables)	6 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended September 30, Six Months Ended September 30, (In thousands, except per share data) 2023 2022 2023 2022 Numerator Net income $ 53,559  $ 51,023  $ 106,835  $ 106,295        Denominator     Denominator for basic earnings per share — weighted average shares outstanding 49,687  49,804  49,727  50,033  Dilutive effect of unvested restricted stock units and options issued to employees and directors 394  461  411  463  Denominator for diluted earnings per share 50,081  50,265  50,138  50,496        Earnings per Common Share:     Basic earnings per share $ 1.08  $ 1.02  $ 2.15  $ 2.12        Diluted earnings per share $ 1.07  $ 1.02  $ 2.13  $ 2.11

v3.23.3

Stock-Based Compensation (Tables)	6 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Compensation Expense Information	The following table provides information regarding our stock-based compensation: Three Months Ended September 30, Six Months Ended September 30, (In thousands) 2023 2022 2023 2022 Pre-tax stock-based compensation costs charged against income $ 3,688  $ 3,466  $ 7,834  $ 7,323  Income tax benefit recognized on compensation costs $ 263  $ 338  $ 669  $ 875  Total fair value of options and RSUs vested during the period $ 987  $ 64  $ 12,213  $ 10,289  Cash received from the exercise of stock options $ 2,155  $ —  $ 9,183  $ 1,489  Tax benefits realized from tax deductions resulting from RSU issuances and stock option exercises $ 263  $ —  $ 1,139  $ 2,895
Summary of Restricted Shares	A summary of the RSUs granted under the 2005 Plan and the 2020 Plan is presented below:       RSUs   Shares (in thousands) Weighted Average Grant-Date Fair Value Six Months Ended September 30, 2022 Unvested at March 31, 2022 440.9  $ 38.45  Granted 148.9  55.04  Incremental performance shares 42.4  —  Vested (222.4) 32.05  Unvested at September 30, 2022 409.8  47.14  Vested at September 30, 2022 108.5  36.54        Six Months Ended September 30, 2023 Unvested at March 31, 2023 409.0  $ 47.17  Granted 157.1  62.06  Incremental performance shares 41.4  —  Vested (205.0) 43.17  Forfeited (8.6) 53.72  Unvested at September 30, 2023 393.9  54.40  Vested at September 30, 2023 110.2  38.77
Fair Value of Options Granted	The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions presented below:   Six Months Ended September 30,   2023   2022 Expected volatility 30.2% - 31.6%   30.8% - 30.9% Expected dividends $ —    $ —  Expected term in years 6.0 to 7.0   6.0 to 7.0 Risk-free rate 3.6% to 4.1%   2.8% to 2.9% Weighted average grant date fair value of options granted $ 23.79  $ 20.10
Stock Option Activity	A summary of option activity under the 2005 Plan and the 2020 Plan is as follows:         Options     Shares (in thousands) Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Six Months Ended September 30, 2022 Outstanding at March 31, 2022 1,100.9  $ 40.62  Granted 197.6  54.48  Exercised (39.1) 38.04  Outstanding at September 30, 2022 1,259.4  42.88  6.6 $ 10,963  Vested at September 30, 2022 830.8  40.04  5.4 $ 9,403  Six Months Ended September 30, 2023         Outstanding at March 31, 2023 1,081.0  $ 43.96  Granted 131.1  61.81  Exercised (230.4) 39.85  Forfeited (35.8) 54.81  Expired (2.8) 54.47  Outstanding at September 30, 2023 943.1  47.00  6.3 $ 10,166  Vested at September 30, 2023 644.7  43.19  5.2 $ 9,025

v3.23.3

Business Segments (Tables)	6 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Operating and Reportable Segments	The tables below summarize information about our reportable segments.   Three Months Ended September 30, 2023 (In thousands) North American OTC Healthcare International OTC Healthcare Consolidated Total segment revenues* $ 244,423  $ 41,893  $ 286,316  Cost of sales 107,466  18,830  126,296  Gross profit 136,957  23,063  160,020  Advertising and marketing 35,389  4,713  40,102  Contribution margin $ 101,568  $ 18,350  $ 119,918  Other operating expenses   31,668  Operating income   $ 88,250  * Intersegment revenues of $0.6 million were eliminated from the North American OTC Healthcare segment.   Six Months Ended September 30, 2023 (In thousands) North American OTC Healthcare International OTC Healthcare Consolidated Total segment revenues* $ 490,566  $ 75,059  $ 565,625  Cost of sales 217,542  33,390  250,932  Gross profit 273,024  41,669  314,693  Advertising and marketing 66,790  9,543  76,333  Contribution margin $ 206,234  $ 32,126  $ 238,360  Other operating expenses   64,916  Operating income   $ 173,444  * Intersegment revenues of $2.0 million were eliminated from the North American OTC Healthcare segment.   Three Months Ended September 30, 2022 (In thousands) North American OTC Healthcare International OTC Healthcare Consolidated Total segment revenues* $ 252,054  $ 37,219  $ 289,273  Cost of sales 113,533  14,731  128,264  Gross profit 138,521  22,488  161,009  Advertising and marketing 39,316  4,503  43,819  Contribution margin $ 99,205  $ 17,985  $ 117,190  Other operating expenses   32,806  Operating income   $ 84,384  * Intersegment revenues of $1.1 million were eliminated from the North American OTC Healthcare segment.   Six Months Ended September 30, 2022 (In thousands) North American OTC Healthcare International OTC Healthcare Consolidated Total segment revenues* $ 494,572  $ 71,760  $ 566,332  Cost of sales 216,454  28,750  245,204  Gross profit 278,118  43,010  321,128  Advertising and marketing 74,728  9,042  83,770  Contribution margin $ 203,390  $ 33,968  $ 237,358  Other operating expenses   65,960  Operating income   $ 171,398  * Intersegment revenues of $1.7 million were eliminated from the North American OTC Healthcare segment.
Revenues from Similar Product Groups	The tables below summarize information about our segment revenues from similar product groups. Three Months Ended September 30, 2023 (In thousands) North American OTC Healthcare International OTC Healthcare Consolidated Analgesics $ 29,976  $ 1,386  $ 31,362  Cough & Cold 25,970  7,263  33,233  Women's Health 55,000  7,072  62,072  Gastrointestinal 38,703  14,061  52,764  Eye & Ear Care 39,745  7,125  46,870  Dermatologicals 33,018  1,469  34,487  Oral Care 19,312  3,469  22,781  Other OTC 2,699  48  2,747  Total segment revenues $ 244,423  $ 41,893  $ 286,316  Six Months Ended September 30, 2023 (In thousands) North American OTC Healthcare International OTC Healthcare Consolidated Analgesics $ 57,158  $ 2,228  $ 59,386  Cough & Cold 46,344  13,315  59,659  Women's Health 109,955  12,028  121,983  Gastrointestinal 83,384  26,971  110,355  Eye & Ear Care 79,216  11,146  90,362  Dermatologicals 67,696  2,807  70,503  Oral Care 41,038  6,491  47,529  Other OTC 5,775  73  5,848  Total segment revenues $ 490,566  $ 75,059  $ 565,625  Three Months Ended September 30, 2022 (In thousands) North American OTC Healthcare International OTC Healthcare Consolidated Analgesics $ 32,750  $ 541  $ 33,291  Cough & Cold 24,058  7,168  31,226  Women's Health 59,379  4,745  64,124  Gastrointestinal 41,272  16,037  57,309  Eye & Ear Care 37,961  4,734  42,695  Dermatologicals 32,872  902  33,774  Oral Care 21,251  3,080  24,331  Other OTC 2,511  12  2,523  Total segment revenues $ 252,054  $ 37,219  $ 289,273  Six Months Ended September 30, 2022 (In thousands) North American OTC Healthcare International OTC Healthcare Consolidated Analgesics $ 60,547  $ 994  $ 61,541  Cough & Cold 45,650  13,439  59,089  Women's Health 120,563  9,612  130,175  Gastrointestinal 81,339  30,064  111,403  Eye & Ear Care 76,572  9,470  86,042  Dermatologicals 62,327  1,908  64,235  Oral Care 42,226  6,250  48,476  Other OTC 5,348  23  5,371  Total segment revenues $ 494,572  $ 71,760  $ 566,332

v3.23.3

Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Mar. 31, 2023
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 22,742	$ 20,634
Work in process	233	220
Finished goods	138,308	141,267
Inventories	$ 161,283	$ 162,121

v3.23.3

Inventories - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2023	Mar. 31, 2023
Inventory Disclosure [Abstract]
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 6.0	$ 5.8

v3.23.3

Goodwill - Schedule of Changes (Details) $ in Thousands	6 Months Ended
	Sep. 30, 2023 USD ($)
Goodwill [Roll Forward]
Goodwill	$ 741,656
Accumulated impairment loss, beginning	(214,103)
Goodwill, net	527,553
Effects of foreign currency exchange rates	(693)
Goodwill, gross, ending	740,963
Accumulated impairment loss, ending	(214,103)
Goodwill, net, ending	526,860
North American OTC Healthcare
Goodwill [Roll Forward]
Goodwill	711,452
Accumulated impairment loss, beginning	(212,516)
Goodwill, net	498,936
Effects of foreign currency exchange rates	0
Goodwill, gross, ending	711,452
Accumulated impairment loss, ending	(212,516)
Goodwill, net, ending	498,936
International OTC Healthcare
Goodwill [Roll Forward]
Goodwill	30,204
Accumulated impairment loss, beginning	(1,587)
Goodwill, net	28,617
Effects of foreign currency exchange rates	(693)
Goodwill, gross, ending	29,511
Accumulated impairment loss, ending	(1,587)
Goodwill, net, ending	$ 27,924

v3.23.3

Goodwill - Narrative (Details) $ in Millions	12 Months Ended
	Mar. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, impairment loss	$ 48.8

v3.23.3

Intangible Assets, net - Activity Affecting Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Mar. 31, 2023
Intangible Assets, Gross [Abstract]
Totals, gross, beginning balance			$ 2,580,020
Totals, effects of foreign currency exchange rate			(3,867)
Totals, gross, ending balance	$ 2,576,153		2,576,153
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Accumulated amortization, beginning balance			238,127
Accumulated amortization, additions	4,900	$ 5,600	9,900	$ 11,300
Accumulated amortization, effects of foreign exchange rates			(124)
Accumulated amortization, ending balance	247,903		247,903
Finite-Lived Intangible Assets, Net [Abstract]
Finite-Lived Intangible Assets, Net	162,430		162,430
Intangible Assets, Net [Abstract]
Intangible Assets, Net (Excluding Goodwill), Total	2,328,250		2,328,250		$ 2,341,893
Finite-Lived Trademarks and Customer Relationships
Finite-Lived Intangible Assets, Gross [Abstract]
Finite-lived trademarks and customer relationships, beginning balance			411,118
Finite-lived trademarks and customer relationships, effects of foreign currency exchange rate			(785)
Finite-lived trademarks and customer relationships, ending balance	410,333		410,333
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Accumulated amortization, beginning balance			238,127
Accumulated amortization, additions			9,900
Accumulated amortization, effects of foreign exchange rates			(124)
Accumulated amortization, ending balance	247,903		247,903
Finite-Lived Intangible Assets, Net [Abstract]
Finite-Lived Intangible Assets, Net	162,430		162,430
Indefinite- Lived Trademarks
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived trademarks, beginning balance			2,168,902
Indefinite lived trademarks, effects of foreign currency exchange rate			(3,082)
Indefinite-lived trademarks, ending balance	$ 2,165,820		$ 2,165,820

v3.23.3

Intangible Assets, net - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Mar. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 4,900	$ 5,600	$ 9,900	$ 11,300
Impairment of intangible assets					$ 321,400
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	10 years		10 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	25 years		25 years

v3.23.3

Intangible Assets, net - Future Amortization of Intangible Assets (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2024 (remaining six months ended March 31, 2024)	$ 9,866
2025	18,061
2026	16,110
2027	14,519
2028	12,183
Thereafter	91,691
Finite-lived intangible assets, net	$ 162,430

v3.23.3

Leases - Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Leases [Abstract]
Amortization of right-of-use assets	$ 664	$ 664	$ 1,329	$ 1,329
Interest on lease liabilities	24	45	54	95
Operating lease cost	1,624	1,617	3,248	3,251
Short term lease cost	34	51	67	85
Variable lease cost	16,941	17,016	33,397	29,015
Total net lease cost	$ 19,287	$ 19,393	$ 38,095	$ 33,775

v3.23.3

Leases - Lease Maturities (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Operating Leases
2024 (remaining six months ending March 31, 2024)	$ 3,564
2025	4,810
2026	2,328
2027	1,913
2028	1,433
Thereafter	254
Total undiscounted lease payments	14,302
Less amount of lease payments representing interest	(926)
Total present value of lease payments	13,376
Finance Lease
2024 (remaining six months ending March 31, 2024)	1,461
2025	1,509
2026	96
2027	80
2028	0
Thereafter	0
Total undiscounted lease payments	3,146
Less amount of lease payments representing interest	(52)
Total present value of lease payments	3,094
Total
2024 (remaining six months ending March 31, 2024)	5,025
2025	6,319
2026	2,424
2027	1,993
2028	1,433
Thereafter	254
Total undiscounted lease payments	17,448
Less amount of lease payments representing interest	(978)
Total present value of lease payments	$ 16,470

v3.23.3

Leases - Additional Information (Details)	Sep. 30, 2023
Weighted average remaining lease term (years)
Operating leases	3 years 7 days
Finance leases	1 year 2 months 23 days
Weighted average discount rate
Operating leases	3.62%
Finance leases	2.94%

v3.23.3

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Mar. 31, 2023
Payables and Accruals [Abstract]
Accrued marketing costs	$ 26,512	$ 30,471
Accrued compensation costs	8,232	14,292
Accrued broker commissions	2,210	1,767
Income taxes payable	8,160	10,645
Accrued professional fees	4,323	4,254
Accrued production costs	6,003	5,700
Other accrued liabilities	4,640	5,395
Total other accrued liabilities	$ 60,080	$ 72,524

v3.23.3

Long-Term Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Sep. 30, 2023	Mar. 31, 2023
Debt Instrument [Line Items]
Total long-term debt (including current portion)	$ 1,275,000
Long-term debt, net	1,275,000	$ 1,360,000
Less: unamortized debt costs	(12,028)	(14,212)
Long-term debt, net	$ 1,262,972	1,345,788
Senior Notes | 2021 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate	3.75%
Total long-term debt (including current portion)	$ 600,000	600,000
Senior Notes | 2019 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate	5.125%
Total long-term debt (including current portion)	$ 400,000	400,000
Term Loans | 2012 Term B-5 Loans
Debt Instrument [Line Items]
Total long-term debt (including current portion)	$ 275,000	$ 360,000
Term Loans | 2012 Term B-5 Loans | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		2.00%
Debt instrument, variable rate, minimum		0.50%
Term Loans | 2012 Term B-5 Loans | Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		1.00%
Term Loans | 2012 Term B-5 Loans | SOFR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	2.00%

v3.23.3

Long-Term Debt - Narrative (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Debt Instrument [Line Items]
Long-term debt outstanding	$ 1,275,000
Revolving Credit Facility | 2012 ABL Revolver
Debt Instrument [Line Items]
Long-term debt outstanding	0
Borrowing capacity	$ 171,200

v3.23.3

Long-Term Debt - Maturities of Long-term Debt (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Aggregate Future Principal Payments
2024 (remaining six months ending March 31, 2024)	$ 0
2025	0
2026	0
2027	0
2028	400,000
Thereafter	875,000
Total long-term debt (including current portion)	$ 1,275,000

v3.23.3

Fair Value Measurements (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Mar. 31, 2023
Senior Notes | 2019 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	$ 400,000	$ 400,000
Senior Notes | 2021 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	600,000	600,000
Term Loans | 2012 Term B-5 Loans | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	275,000	360,000
Fair Value, Measurements, Recurring | Senior Notes | 2019 Senior Notes | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	373,000	383,500
Fair Value, Measurements, Recurring | Senior Notes | 2021 Senior Notes | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	482,250	510,750
Fair Value, Measurements, Recurring | Term Loans | 2012 Term B-5 Loans | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	$ 275,000	$ 359,550

v3.23.3

Stockholders' Equity - Narrative (Details)	6 Months Ended
	Sep. 30, 2023 USD ($) vote $ / shares shares	May 02, 2023 USD ($)	Mar. 31, 2023 $ / shares shares
Stockholders' Equity Note [Abstract]
Common stock, shares authorized (in shares) | shares	250,000,000		250,000,000
Common stock, par value (in USD per share) | $ / shares	$ 0.01		$ 0.01
Preferred stock, shares authorized (in shares) | shares	5,000,000		5,000,000
Preferred stock, par value (in USD per share) | $ / shares	$ 0.01		$ 0.01
Voting rights, number of votes per common share owned | vote	1
Dividends declared on common stock | $	$ 0
Stock repurchase program, authorized amount | $		$ 25,000,000

v3.23.3

Stockholders' Equity - Schedule of Repurchased Shares (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Class of Stock [Line Items]
Total amount repurchased		$ 12,273	$ 30,547	$ 55,450
Share Repurchase Program
Class of Stock [Line Items]
Number of shares (in shares)	0	236,681	426,479	914,236
Average price per share (in USD per share)	$ 0	$ 51.85	$ 58.62	$ 54.69
Total amount repurchased	$ 0	$ 12,300	$ 25,000	$ 50,000
Restricted Shares
Class of Stock [Line Items]
Number of shares (in shares)	0	0	88,953	99,219
Average price per share (in USD per share)	$ 0	$ 0	$ 61.92	$ 54.94
Total amount repurchased	$ 0	$ 0	$ 5,500	$ 5,500

v3.23.3

Accumulated Other Comprehensive Loss - Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	$ 1,535,959	$ 1,480,295	$ 1,447,084	$ 1,619,841	$ 1,584,743	$ 1,577,611
Accumulated other comprehensive loss, net of tax
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	(35,994)	$ (32,210)	(31,564)	$ (36,459)	$ (29,341)	$ (19,032)
Cumulative translation adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	(36,710)		(32,280)
Unrecognized net gain on pension plans, net of tax of $(214) and $(214), respectively
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	716		716
Unrecognized net gain on pension plan, tax	$ (214)		$ (214)

v3.23.3

Accumulated Other Comprehensive Loss - Narrative (Details) - USD ($)	6 Months Ended	12 Months Ended
	Sep. 30, 2023	Mar. 31, 2023
Stockholders' Equity Note [Abstract]
Reclassification from accumulated other comprehensive loss into earnings	$ 0	$ 0

v3.23.3

Earnings Per Share - Computation of Basis and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Numerator
Net income	$ 53,559	$ 51,023	$ 106,835	$ 106,295
Denominator
Denominator for basic earnings per share — weighted average shares outstanding (in shares)	49,687	49,804	49,727	50,033
Dilutive effect of unvested restricted stock units and options issued to employees and directors (in shares)	394	461	411	463
Denominator for diluted earnings per share (in shares)	50,081	50,265	50,138	50,496
Earnings per Common Share:
Basic earnings per share (in USD per share)	$ 1.08	$ 1.02	$ 2.15	$ 2.12
Diluted earnings per share (in USD per share)	$ 1.07	$ 1.02	$ 2.13	$ 2.11

v3.23.3

Earnings Per Share - Antidilutive Securities (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Outstanding Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	0.3	0.4	0.3	0.4

v3.23.3

Stock-Based Compensation - Narrative (Details) - USD ($) $ in Millions	1 Months Ended	6 Months Ended
	Jun. 30, 2014	Sep. 30, 2023	Jun. 23, 2020	May 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs related to nonvested awards		$ 3.8
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition (years)		2 years 1 month 6 days
Shares available for issuance under the Plan (in shares)		1,900,000
Options exercised, aggregate intrinsic value		$ 4.7
Restricted Stock Units (RSUs) & Performance Stock Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs related to nonvested awards		$ 14.8
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition (years)		1 year 10 months 24 days
Long-term Equity Incentive Plan, 2005
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for grant (in shares)				5,000,000
Number of additional shares authorized (in shares)	1,800,000
Long-term Incentive Plan, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)			2,827,210
Number of new shares for future issuance under 2020 long-term incentive plans (in shares)			2,000,000
Number of unissued shares reserved for 2020 long-term incentive plans (in shares)			827,210

v3.23.3

Stock-Based Compensation - Stock Based Compensation Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Pre-tax stock-based compensation costs charged against income	$ 3,688	$ 3,466	$ 7,834	$ 7,323
Income tax benefit recognized on compensation costs	263	338	669	875
Total fair value of options and RSUs vested during the period	987	64	12,213	10,289
Cash received from the exercise of stock options	2,155	0	9,183	1,489
Tax benefits realized from tax deductions resulting from RSU issuances and stock option exercises	$ 263	$ 0	$ 1,139	$ 2,895

v3.23.3

Stock-Based Compensation - Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) - $ / shares	6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Shares
Outstanding, beginning of period (in shares)	409,000.0	440,900
Granted (in shares)	157,100	148,900
Incremental performance shares (in shares)	41,400	42,400
Vested (in shares)	(205,000.0)	(222,400)
Forfeited (in shares)	(8,600)
Outstanding, end of period (in shares)	393,900	409,800
Vested, end of period (in shares)	110,200	108,500
Weighted Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)	$ 47.17	$ 38.45
Granted, weighted-average grant-date fair value (in USD per share)	62.06	55.04
Vested, weighted-average grant-date fair value (in USD per share)	43.17	32.05
Forfeited, weighted-average grant-date fair value (in USD per share)	53.72
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)	54.40	47.14
Vested, end of period, weighted-average grant-date fair value (in USD per share)	$ 38.77	$ 36.54

v3.23.3

Stock-Based Compensation - Stock Option Valuation Assumptions (Details) - Stock Options - USD ($)	6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividends	$ 0	$ 0
Granted, weighted-average grant-date fair value (in USD per share)	$ 23.79	$ 20.10
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	30.20%	30.80%
Expected term in years	6 years	6 years
Risk-free rate	3.60%	2.80%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	31.60%	30.90%
Expected term in years	7 years	7 years
Risk-free rate	4.10%	2.90%

v3.23.3

Stock-Based Compensation - Stock Option Activity (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) $ / shares shares
Shares
Outstanding, beginning of period (in shares) | shares	1,081,000	1,100,900
Granted (in shares) | shares	131,100	197,600
Exercised (in shares) | shares	(230,400)	(39,100)
Forfeited (in shares) | shares	(35,800)
Expired (in shares) | shares	(2,800)
Outstanding, end of period (in shares) | shares	943,100	1,259,400
Exercisable, end of period (in shares) | shares	644,700	830,800
Weighted Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share) | $ / shares	$ 43.96	$ 40.62
Granted, weighted-average exercise price (in USD per share) | $ / shares	61.81	54.48
Exercised, weighted-average exercise price (in USD per share) | $ / shares	39.85	38.04
Forfeited, weighted-average exercise price (in USD per share) | $ / shares	54.81
Expired, weighted-average exercise price (in USD per share) | $ / shares	54.47
Outstanding, end of period, weighted-average exercise price (in USD per share) | $ / shares	47.00	42.88
Exercisable, end of period, weighted-average exercise price (in USD per share) | $ / shares	$ 43.19	$ 40.04
Options, Additional Disclosures:
Outstanding, end of period, weighted-average remaining contractual term	6 years 3 months 18 days	6 years 7 months 6 days
Exercisable, end of period, weighted-average remaining contractual term	5 years 2 months 12 days	5 years 4 months 24 days
Outstanding, end of period, aggregate intrinsic value | $	$ 10,166	$ 10,963
Exercisable, end of period, aggregate intrinsic value | $	$ 9,025	$ 9,403

v3.23.3

Income Taxes (Details)	3 Months Ended		6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Effective income tax rate	23.90%	23.40%	23.20%	22.70%

v3.23.3

Concentrations of Risk (Details) - manufacturer	3 Months Ended		6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Concentration Risk [Line Items]
Number of third-party manufacturers	128	130	128	130
Sales | Customer Concentration Risk | Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	19.10%	19.70%	20.00%	19.80%
Sales | Customer Concentration Risk | Amazon
Concentration Risk [Line Items]
Concentration risk, percentage			10.30%
Sales | Customer Concentration Risk | Walgreens
Concentration Risk [Line Items]
Concentration risk, percentage		10.40%
Sales | Supplier Concentration Risk
Concentration Risk [Line Items]
Number of third-party manufacturers with long-term contracts			28	27
Top 5 brands | Sales | Product Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	38.90%	39.70%	40.00%	40.60%
Manufacturers | Sales | Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage			74.60%	71.30%

v3.23.3

Business Segments - Information on Operating and Reportable Segments (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information, Profit (Loss):
Total revenues	$ 286,316	$ 289,273	$ 565,625	$ 566,332
Cost of sales	126,296	128,264	250,932	245,204
Gross profit	160,020	161,009	314,693	321,128
Advertising and marketing	40,102	43,819	76,333	83,770
Contribution margin	119,918	117,190	238,360	237,358
Other operating expenses	31,668	32,806	64,916	65,960
Operating income	88,250	84,384	173,444	171,398
North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	244,423	252,054	490,566	494,572
International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	41,893	37,219	75,059	71,760
Operating Segments | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	244,423	252,054	490,566	494,572
Cost of sales	107,466	113,533	217,542	216,454
Gross profit	136,957	138,521	273,024	278,118
Advertising and marketing	35,389	39,316	66,790	74,728
Contribution margin	101,568	99,205	206,234	203,390
Operating Segments | International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	41,893	37,219	75,059	71,760
Cost of sales	18,830	14,731	33,390	28,750
Gross profit	23,063	22,488	41,669	43,010
Advertising and marketing	4,713	4,503	9,543	9,042
Contribution margin	18,350	17,985	32,126	33,968
Intersegment Eliminations | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	$ 600	$ 1,100	$ 2,000	$ 1,700

v3.23.3

Business Segments - Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	$ 286,316	$ 289,273	$ 565,625	$ 566,332
Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	31,362	33,291	59,386	61,541
Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	33,233	31,226	59,659	59,089
Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	62,072	64,124	121,983	130,175
Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	52,764	57,309	110,355	111,403
Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	46,870	42,695	90,362	86,042
Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	34,487	33,774	70,503	64,235
Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	22,781	24,331	47,529	48,476
Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	2,747	2,523	5,848	5,371
North American OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	244,423	252,054	490,566	494,572
North American OTC Healthcare | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	29,976	32,750	57,158	60,547
North American OTC Healthcare | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	25,970	24,058	46,344	45,650
North American OTC Healthcare | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	55,000	59,379	109,955	120,563
North American OTC Healthcare | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	38,703	41,272	83,384	81,339
North American OTC Healthcare | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	39,745	37,961	79,216	76,572
North American OTC Healthcare | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	33,018	32,872	67,696	62,327
North American OTC Healthcare | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	19,312	21,251	41,038	42,226
North American OTC Healthcare | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	2,699	2,511	5,775	5,348
International OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	41,893	37,219	75,059	71,760
International OTC Healthcare | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	1,386	541	2,228	994
International OTC Healthcare | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	7,263	7,168	13,315	13,439
International OTC Healthcare | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	7,072	4,745	12,028	9,612
International OTC Healthcare | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	14,061	16,037	26,971	30,064
International OTC Healthcare | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	7,125	4,734	11,146	9,470
International OTC Healthcare | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	1,469	902	2,807	1,908
International OTC Healthcare | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	3,469	3,080	6,491	6,250
International OTC Healthcare | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	$ 48	$ 12	$ 73	$ 23

---